353 related articles for article (PubMed ID: 23306062)
1. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.
Laine A; Sihto H; Come C; Rosenfeldt MT; Zwolinska A; Niemelä M; Khanna A; Chan EK; Kähäri VM; Kellokumpu-Lehtinen PL; Sansom OJ; Evan GI; Junttila MR; Ryan KM; Marine JC; Joensuu H; Westermarck J
Cancer Discov; 2013 Feb; 3(2):182-97. PubMed ID: 23306062
[TBL] [Abstract][Full Text] [Related]
2. Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
Zhao Q; Zhao M; Parris AB; Xing Y; Yang X
Int J Oncol; 2016 Sep; 49(3):1203-10. PubMed ID: 27574003
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathways: harnessing E2F1 regulation for prosenescence therapy in p53-defective cancer cells.
Laine A; Westermarck J
Clin Cancer Res; 2014 Jul; 20(14):3644-50. PubMed ID: 24788101
[TBL] [Abstract][Full Text] [Related]
4. Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients.
Lucas CM; Harris RJ; Holcroft AK; Scott LJ; Carmell N; McDonald E; Polydoros F; Clark RE
Leukemia; 2015 Jul; 29(7):1514-23. PubMed ID: 25765543
[TBL] [Abstract][Full Text] [Related]
5. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
6. IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells.
Zuo S; Liu C; Wang J; Wang F; Xu W; Cui S; Yuan L; Chen X; Fan W; Cui M; Song G
J Cancer Res Clin Oncol; 2012 Jun; 138(6):1045-55. PubMed ID: 22392074
[TBL] [Abstract][Full Text] [Related]
7. Increase in CIP2A expression is associated with doxorubicin resistance.
Choi YA; Park JS; Park MY; Oh KS; Lee MS; Lim JS; Kim KI; Kim KY; Kwon J; Yoon DY; Moon EY; Yang Y
FEBS Lett; 2011 Mar; 585(5):755-60. PubMed ID: 21241697
[TBL] [Abstract][Full Text] [Related]
8. p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase.
Zemskova M; Lilly MB; Lin YW; Song JH; Kraft AS
Mol Cancer Res; 2010 Aug; 8(8):1126-41. PubMed ID: 20647331
[TBL] [Abstract][Full Text] [Related]
9. Cancerous inhibitor of protein phosphatase 2A contributes to human papillomavirus oncoprotein E7-induced cell proliferation via E2F1.
Zhang W; Chen H; Chen Y; Liu J; Wang X; Yu X; Chen JJ; Zhao W
Oncotarget; 2015 Mar; 6(7):5253-62. PubMed ID: 25650660
[TBL] [Abstract][Full Text] [Related]
10. E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
Li Y; Shao J; Shen K; Xu Y; Liu J; Qian X
J Cell Biochem; 2012 Oct; 113(10):3165-77. PubMed ID: 22593008
[TBL] [Abstract][Full Text] [Related]
11. E2F-1 is a critical modulator of cellular senescence in human cancer.
Park C; Lee I; Kang WK
Int J Mol Med; 2006 May; 17(5):715-20. PubMed ID: 16596252
[TBL] [Abstract][Full Text] [Related]
12. TIGAR induces p53-mediated cell-cycle arrest by regulation of RB-E2F1 complex.
Madan E; Gogna R; Kuppusamy P; Bhatt M; Pati U; Mahdi AA
Br J Cancer; 2012 Jul; 107(3):516-26. PubMed ID: 22782351
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor NF-Y induces apoptosis in cells expressing wild-type p53 through E2F1 upregulation and p53 activation.
Gurtner A; Fuschi P; Martelli F; Manni I; Artuso S; Simonte G; Ambrosino V; Antonini A; Folgiero V; Falcioni R; Sacchi A; Piaggio G
Cancer Res; 2010 Dec; 70(23):9711-20. PubMed ID: 20952509
[TBL] [Abstract][Full Text] [Related]
14. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Khanna A; Pimanda JE; Westermarck J
Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
[TBL] [Abstract][Full Text] [Related]
15. CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis.
Laine A; Nagelli SG; Farrington C; Butt U; Cvrljevic AN; Vainonen JP; Feringa FM; Grönroos TJ; Gautam P; Khan S; Sihto H; Qiao X; Pavic K; Connolly DC; Kronqvist P; Elo LL; Maurer J; Wennerberg K; Medema RH; Joensuu H; Peuhu E; de Visser K; Narla G; Westermarck J
Cancer Res; 2021 Aug; 81(16):4319-4331. PubMed ID: 34145035
[TBL] [Abstract][Full Text] [Related]
16. CIP2A is overexpressed in gastric cancer and its depletion leads to impaired clonogenicity, senescence, or differentiation of tumor cells.
Li W; Ge Z; Liu C; Liu Z; Björkholm M; Jia J; Xu D
Clin Cancer Res; 2008 Jun; 14(12):3722-8. PubMed ID: 18559589
[TBL] [Abstract][Full Text] [Related]
17. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
18. E2F1-activated SPIN1 promotes tumor growth via a MDM2-p21-E2F1 feedback loop in gastric cancer.
Lv BB; Ma RR; Chen X; Zhang GH; Song L; Wang SX; Wang YW; Liu HT; Gao P
Mol Oncol; 2020 Oct; 14(10):2629-2645. PubMed ID: 32767629
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of CIP2A in estrogen depletion-resistant breast cancer cells treated with low-dose everolimus.
Nishio E; Hayashi T; Akaza M; Hisatomi Y; Hikichi M; Fujii T; Utsumi T; Harada N; Shimono Y
FEBS Open Bio; 2020 Oct; 10(10):2072-2080. PubMed ID: 32810922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
